Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 5/20 | 0.54 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TLR4 | O00206 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30678236 | 0.88 | MAOB (0.66) | MAOBKMT2ANR4A2SMPD1MAOA | |
| SCHEMBL4200015 | 0.88 | MAOB (0.66) | MAOBKMT2ANR4A2SMPD1MAOA | |
| SCHEMBL5866349 | 0.87 | GPR132 (0.59) | GPR132 | |
| SCHEMBL5605259 | 0.86 | SMPD1 (0.65) | MAOBKMT2ANR4A2SMPD1MAOA | |
| SCHEMBL5605085 | 0.85 | MAOB (0.68) | MAOBKMT2ANR4A2SMPD1MAOA | |
| SCHEMBL5604959 | 0.83 | SMPD1 (0.63) | MAOBKMT2ANR4A2SMPD1MAOA | |
| SCHEMBL7163295 | 0.82 | MRGPRX4 (0.62) | SLC2A1SLC2A4MAOBGPR132NR4A2 | |
| SCHEMBL5746806 | 0.81 | GPR132 (0.52) | MAOBKMT2AGPR132NR4A2KDM4E | |
| SCHEMBL25720168 | 0.80 | LMNA (0.50) | KMT2AKDM4E | |
| SCHEMBL7160639 | 0.80 | NR4A2 (0.77) | MAOBKMT2AGPR132NR4A2SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144889-B2 | Triarylimidazoles | HOFFMAN-LA ROCHE INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1675848-A1 | NOVEL TRIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005040153-A1 | NOVEL TRIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050085473-A1 | Novel triarylimidazoles | HOFFMANN-LA ROCHE INC. | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085473-A1 | Novel triarylimidazoles | AURKAIP1, GLS2, GOT2 | SLC2A1 4100/4885SLC2A4 4031/4885MAOB 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.